VPS53 Antibody

What is VPS53 and what cellular functions does it perform?

VPS53 (Vacuolar protein sorting-associated protein 53 homolog) serves as a critical component of two distinct multiprotein complexes with specialized cellular functions. First, it acts as a component of the Golgi-associated retrograde protein (GARP) complex involved in retrograde transport from early and late endosomes to the trans-Golgi network (TGN) . Second, VPS53 functions as a component of the endosome-associated recycling protein (EARP) complex involved in endocytic recycling . The EARP complex specifically associates with Rab4-positive endosomes and promotes recycling of internalized transferrin receptor (TFRC) to the plasma membrane . VPS53's role in the GARP complex is particularly important for maintaining the cycling of mannose 6-phosphate receptors between the TGN and endosomes, which is necessary for proper lysosomal sorting of acid hydrolases such as CTSD .

What types of VPS53 antibodies are commercially available for research?

Based on current data, researchers have access to both polyclonal and monoclonal antibodies targeting VPS53. The commercially available options include rabbit polyclonal antibodies (e.g., ab106469, ab251759, A06836) and mouse monoclonal antibodies (e.g., 67610-1-PBS, 67610-1-Ig) . These antibodies vary in their immunogen design, with some targeting synthetic peptides from the carboxy terminus region of human VPS53 , others using recombinant fragment proteins within human VPS53 amino acids 750 to C-terminus , and yet others utilizing VPS53 fusion proteins . This diversity allows researchers to select antibodies specifically suited to their experimental needs.

For which experimental applications are VPS53 antibodies validated?

VPS53 antibodies have been validated for multiple experimental applications essential to cellular and molecular research. The primary validated applications include Western Blot (WB), Immunohistochemistry (IHC), Immunocytochemistry/Immunofluorescence (ICC/IF), and Enzyme-Linked Immunosorbent Assay (ELISA) . Specific antibodies have demonstrated reactivity in various cell lines including U2OS, HeLa, NIH/3T3, HEK-293, HepG2, Jurkat, K-562, HSC-T6, LNCaP, and 4T1 cells . For tissue samples, positive IHC detection has been reported in human liver tissue and rat brain tissue . This broad application profile enables researchers to employ VPS53 antibodies across diverse experimental platforms.

What are the species reactivity profiles of VPS53 antibodies?

Most commercially available VPS53 antibodies show cross-reactivity with human, mouse, and rat samples . This cross-species reactivity is advantageous for comparative studies and translational research between model organisms and human systems. Some antibodies may have predicted reactivity with additional species based on sequence homology, though these predictions should be experimentally verified before use in critical experiments . The conservation of VPS53 across mammalian species suggests fundamental roles in cellular trafficking that have been preserved throughout evolution.

What are the optimal antigen retrieval methods for VPS53 immunohistochemistry?

For optimal VPS53 detection in formalin-fixed paraffin-embedded (FFPE) tissue sections, heat-induced epitope retrieval (HIER) methods have shown superior results. The recommended approach uses TE buffer at pH 9.0 , which more effectively exposes the epitopes in VPS53 protein. Alternatively, researchers may perform antigen retrieval with citrate buffer at pH 6.0 , though this may yield less consistent results depending on tissue fixation conditions and duration. The chosen method should be optimized according to tissue type, fixation parameters, and the specific VPS53 antibody employed. Complete antigen retrieval protocols should include appropriate incubation times (typically 15-20 minutes) and cooling periods to minimize background staining while maximizing specific signal detection.

How can researchers troubleshoot discrepancies in VPS53 molecular weight detection?

VPS53 antibodies have detected varying molecular weights in experimental settings, with values ranging from 68 kDa to 94 kDa . The calculated molecular weight based on amino acid sequence is approximately 94 kDa for the 832 amino acid form , while other calculations suggest approximately 79.7 kDa . These discrepancies may result from multiple factors including post-translational modifications, alternative splicing variants, proteolytic processing, or technical variations in gel electrophoresis systems. To troubleshoot inconsistent molecular weight detection, researchers should:

• Verify sample preparation protocols, including protein denaturation conditions

• Compare reducing versus non-reducing conditions

• Employ gradient gels to improve resolution in the relevant molecular weight range

• Consider the use of multiple antibodies targeting different epitopes to confirm protein identity

• Perform mass spectrometry validation for definitive molecular weight determination

What experimental approaches can verify VPS53 antibody specificity in cellular contexts?

To rigorously validate VPS53 antibody specificity, researchers should implement multiple complementary approaches:

• Genetic manipulation: Compare antibody signals in wild-type versus VPS53 knockout/knockdown cells using CRISPR-Cas9 or siRNA techniques

• Competitive binding assays: Pre-incubate antibody with excess immunogen peptide to demonstrate signal reduction in subsequent applications

• Heterologous expression systems: Overexpress tagged VPS53 constructs and confirm co-localization with antibody signal

• Multiple antibody validation: Compare staining patterns using antibodies raised against different VPS53 epitopes

• Subcellular fractionation: Confirm enrichment of VPS53 signal in fractions containing the trans-Golgi network and endosomal compartments

• Co-immunoprecipitation: Verify interaction with known VPS53 binding partners such as other GARP or EARP complex components (VPS51, VPS52, VPS54)

These approaches collectively provide strong evidence for antibody specificity when consistent results are obtained across multiple validation methods.

How can researchers distinguish between GARP-associated and EARP-associated VPS53 in experimental settings?

Distinguishing VPS53's participation in the GARP versus EARP complexes requires specialized experimental approaches that exploit the unique components and localizations of each complex:

• Co-immunoprecipitation with complex-specific partners: Use antibodies against VPS54 (GARP-specific) versus Syndetin/VPS50 (EARP-specific) to pull down different VPS53 pools

• Subcellular fractionation: GARP-associated VPS53 predominantly localizes to trans-Golgi network membranes, while EARP-associated VPS53 localizes to Rab4-positive endosomes

• Proximity ligation assay (PLA): Detect in situ protein interactions between VPS53 and complex-specific partners

• Immunofluorescence co-localization: Perform triple staining with VPS53 antibody and markers for TGN (e.g., TGN46) versus early recycling endosomes (e.g., Rab4)

• Structure-function analysis: Express truncated VPS53 variants that selectively incorporate into either GARP or EARP complexes based on domain requirements

These approaches can provide valuable insights into the distinct pools of VPS53 and their specialized functions within different cellular trafficking pathways.

What controls should be implemented when using VPS53 antibodies in experimental systems?

Robust experimental design with VPS53 antibodies requires comprehensive controls:

• Positive controls:

  • Cell lines with confirmed VPS53 expression (e.g., HEK-293, U2OS, HeLa cells)

  • Tissues with established VPS53 expression (e.g., human liver, rat brain)

  • Recombinant VPS53 protein or overexpression systems

• Negative controls:

  • VPS53 knockdown/knockout cells via CRISPR-Cas9 or siRNA

  • Secondary antibody-only controls to assess non-specific binding

  • Isotype controls using non-specific IgG of the same host species

  • Pre-immune serum (for polyclonal antibodies)

• Validation controls:

  • Peptide competition/blocking experiments using the immunizing antigen

  • Alternative antibodies targeting different VPS53 epitopes

  • Parallel detection with orthogonal methods (e.g., mass spectrometry)

Implementing these controls systematically ensures reliable interpretation of experimental results and minimizes the risk of artifacts or non-specific signals.

How should researchers design experiments to study VPS53 in the context of vesicular trafficking pathways?

To effectively study VPS53's role in vesicular trafficking, researchers should design experiments that capture the dynamic nature of trafficking events:

• Cargo tracking assays:

  • Monitor retrograde transport of mannose 6-phosphate receptors between endosomes and TGN

  • Track recycling of transferrin receptor from endosomes to plasma membrane

  • Assess lysosomal enzyme sorting using cathepsin D trafficking as readout

• Live-cell imaging approaches:

  • Express fluorescently tagged VPS53 constructs for real-time visualization

  • Employ photoactivatable or photoconvertible cargo proteins to track specific trafficking cohorts

  • Use FRAP (Fluorescence Recovery After Photobleaching) to measure dynamic exchange of VPS53 between cytosolic and membrane-bound pools

• Functional perturbation strategies:

  • Deploy dominant-negative VPS53 constructs targeting specific functional domains

  • Utilize acute protein depletion methods (e.g., auxin-inducible degron systems) to avoid compensatory mechanisms

  • Employ temporally controlled gene editing to study immediate versus adaptive responses to VPS53 loss

• Interaction mapping:

  • Identify binding partners using BioID or APEX proximity labeling in specific subcellular compartments

  • Map interaction surfaces through mutagenesis of key residues followed by co-immunoprecipitation

  • Perform crosslinking mass spectrometry to capture transient trafficking complex interactions

These multifaceted approaches collectively provide mechanistic insights into VPS53's functions within complex trafficking networks.

What experimental strategies can resolve contradictory findings about VPS53 molecular weight and isoforms?

To resolve discrepancies regarding VPS53 molecular weight and potential isoforms, researchers should implement a systematic analytical workflow:

• Comprehensive transcriptome analysis:

  • Perform RNA-Seq to identify alternative transcripts

  • Use 5' and 3' RACE to characterize transcript ends

  • Validate transcript expression by RT-PCR with isoform-specific primers

• Protein-level analyses:

  • Employ gradient gels and extended separation times for optimal resolution

  • Compare reducing vs. non-reducing conditions to assess disulfide bonding effects

  • Analyze tissue-specific and cell type-specific expression patterns of potential isoforms

  • Use 2D gel electrophoresis to separate based on both pI and molecular weight

• Post-translational modification mapping:

  • Perform phospho-specific Western blotting with and without phosphatase treatment

  • Use mass spectrometry to comprehensively map modifications (phosphorylation, ubiquitination, etc.)

  • Employ mobility shift assays to detect modification-dependent changes in migration

• Definitive protein characterization:

  • Express recombinant VPS53 variants and compare migration patterns

  • Perform limited proteolysis to identify stable domains and potential processing sites

  • Use absolute quantification mass spectrometry (AQUA) with isotope-labeled peptide standards

This integrated approach can distinguish genuine isoforms from technical artifacts and provide a comprehensive profile of VPS53 molecular species across biological contexts.

How can VPS53 antibodies be employed to study neurodegenerative conditions?

VPS53 mutations have been linked to progressive cerebello-cerebral atrophy type 2 , suggesting important functions in neuronal homeostasis. Researchers investigating neurodegenerative conditions can utilize VPS53 antibodies through the following methodological approaches:

• Comparative neuropathology:

  • Analyze VPS53 expression and localization in post-mortem brain tissues from patients versus controls

  • Perform double immunolabeling with markers of neuronal subtypes to identify vulnerable populations

  • Quantify co-localization with markers of endosomal/lysosomal stress across disease stages

• Animal model characterization:

  • Generate knock-in models harboring disease-associated VPS53 mutations

  • Assess developmental and age-dependent changes in VPS53 distribution in relevant brain regions

  • Correlate VPS53 dysfunction with neuronal protein aggregation, axonal transport, and synaptic integrity

• Cell-based disease modeling:

  • Derive patient-specific iPSCs and differentiate into relevant neuronal subtypes

  • Perform high-content imaging to quantify endosomal morphology, size, and distribution

  • Track the trafficking of neuron-specific cargoes (e.g., neurotrophin receptors, synaptic proteins)

• Therapeutic development platforms:

  • Screen for compounds that correct trafficking defects in cells expressing mutant VPS53

  • Assess antibody-based proximity labeling to identify compensatory pathways that could be therapeutically targeted

  • Develop organoid models to evaluate the impact of VPS53 dysfunction on three-dimensional tissue architecture

These approaches can provide significant insights into the role of vesicular trafficking in neurodegeneration and identify potential therapeutic strategies.

What methodological considerations are important when studying VPS53 in human tissue samples?

When investigating VPS53 in human tissue samples, researchers should address several critical methodological considerations:

• Tissue preservation and fixation:

  • Optimize fixation protocols to preserve VPS53 epitopes while maintaining tissue morphology

  • Compare performance in frozen versus FFPE sections for specific antibodies

  • Assess time-dependent fixation artifacts that may affect VPS53 detection

• Antigen retrieval optimization:

  • Test multiple retrieval buffers (citrate pH 6.0 versus TE pH 9.0) for optimal signal-to-noise ratio

  • Determine optimal retrieval duration and temperature for specific tissue types

  • Consider enzymatic retrieval alternatives for highly crosslinked samples

• Signal amplification and multiplex analysis:

  • Employ tyramide signal amplification for low-abundance detection

  • Utilize multiplex immunofluorescence to correlate VPS53 with other trafficking markers

  • Implement spectral unmixing for analysis of complex tissue environments

• Quantification strategies:

  • Develop automated image analysis workflows to quantify VPS53 expression levels

  • Use digital pathology approaches to correlate VPS53 patterns with clinical parameters

  • Implement machine learning algorithms to identify subtle alterations in subcellular distribution

• Validation across diverse samples:

  • Account for variables such as post-mortem interval, age, and comorbidities

  • Include appropriate demographic diversity in sample cohorts

  • Address batch effects through standardized protocols and reference standards

These methodological considerations ensure robust and reproducible analysis of VPS53 in human tissue samples across research applications.

What storage and handling protocols maximize VPS53 antibody stability and performance?

Proper storage and handling of VPS53 antibodies is critical for maintaining reactivity and specificity over time. Based on manufacturer recommendations:

• Storage conditions:

  • Store antibodies at -20°C for long-term preservation (up to one year)

  • Some antibodies may be stored at -80°C for extended stability

  • Short-term storage at 4°C is viable for up to three months for some preparations

  • Avoid repeated freeze-thaw cycles that decrease antibody activity

• Buffer formulations:

  • Different antibodies are supplied in specific buffer systems:

    • PBS with 0.02% sodium azide and 50% glycerol (pH 7.3)

    • PBS only

    • PBS containing 0.02% sodium azide

  • The presence of glycerol and stabilizing proteins (e.g., BSA) in smaller aliquots (20μl) may enhance stability

• Handling precautions:

  • Aliquot stock solutions upon first thaw to minimize freeze-thaw cycles

  • Use sterile technique when handling antibody solutions

  • Avoid prolonged exposure to high temperatures

  • Centrifuge briefly before opening vials to collect solution at the bottom

• Working dilution preparation:

  • Prepare working dilutions immediately before use

  • Dilute in buffers containing 1-5% blocking protein for enhanced stability

  • Use sterile tubes and buffers for dilution preparation

Following these storage and handling protocols will help ensure consistent antibody performance across experiments and over time.

What experimental parameters influence successful VPS53 detection in challenging sample types?

Detection of VPS53 in challenging samples requires optimization of multiple experimental parameters:

• Sample preparation factors:

  • For fixed tissues:

    • Optimize fixation duration to balance antigen preservation and penetration

    • Section thickness affects antibody penetration (5-10μm optimal for most applications)

    • Fresh frozen versus aldehyde-fixed preparation significantly impacts epitope accessibility

  • For cell lysates:

    • Lysis buffer composition affects solubilization of membrane-associated VPS53

    • Detergent selection (e.g., CHAPS vs. Triton X-100) influences recovery of complex-associated VPS53

    • Protease and phosphatase inhibitors prevent post-lysis modifications

• Detection system optimization:

  • Signal amplification methods for low-abundance samples:

    • Tyramide signal amplification for immunohistochemistry

    • Enhanced chemiluminescence systems with extended exposure for Western blots

    • Photomultiplier gain adjustment for immunofluorescence

  • Background reduction strategies:

    • Extended blocking periods (2-16 hours) with mixed blocking agents

    • Signal-to-noise optimization through titration of primary and secondary antibodies

    • Addition of detergents (0.1-0.3% Triton X-100/Tween-20) to reduce non-specific binding

• Application-specific approaches:

  • For Western blot:

    • Transfer conditions optimization for high molecular weight proteins

    • Membrane selection (PVDF versus nitrocellulose) affects sensitivity and background

  • For immunofluorescence:

    • Mounting media selection affects signal preservation

    • Confocal acquisition parameters require optimization for membrane-associated proteins

Systematic optimization of these parameters enables successful VPS53 detection even in challenging experimental contexts.